Skystar Bio-Pharmaceutical Company  

(Public, NASDAQ:SKBI)   Watch this stock  
Find more results for SKBI
5.54
+0.03 (0.54%)
Real-time:   12:46PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.45 - 5.54
52 week 1.00 - 7.43
Open 5.53
Vol / Avg. 4,429.00/82,307.00
Mkt cap 42.13M
P/E 5.23
Div/yield     -
EPS 1.06
Shares 7.60M
Beta 0.83
Inst. own 12%
Apr 1, 2014
Q4 2013 SKYSTAR BIO-PHARMACEUTICAL COMPANY Earnings Conference Call - Webcast
Mar 31, 2014
Q4 2013 SKYSTAR BIO-PHARMACEUTICAL COMPANY Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 23.35% 18.50%
Operating margin 29.62% 25.46%
EBITD margin - 29.74%
Return on average assets 11.49% 5.66%
Return on average equity 14.28% 6.74%
Employees 317 -
CDP Score - -

Address

4/F, Building B, Chuangye Square No.48 Keji Road Gaoxin District
XI'AN, SXI 710065
China
+86-29-88193188 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Skystar Bio-Pharmaceutical Company (Skystar) is a holding company. The Company is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. It has four product lines: micro-organism products line, which include over 16 products; veterinary medicine line for poultry and livestock, which includes over 245 products; feed additives line, which includes over 16 products, and bio-pharmaceutical veterinary vaccine line, which includes over 10 products. All of the Company�s operations are carried out by Xi�an Tianxing Bio-Pharmaceutical Co., Limited (Xi�an Tianxing), a People�s Republic of China (PRC) joint stock company that the Company controls through contractual arrangements originally between Skystar Bio-Pharmaceutical (Cayman) Holdings Co., Ltd. (Skystar Cayman) and Xi�an Tianxing. As of December 31, 2011, it had over 3,846 customers in 29 provinces in China.

Officers and directors

Weibing Lu Chairman of the Board, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Bing Mei Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Wei Wen Secretary, Director
Age: 45
Bio & Compensation  - Reuters
R. Scott Cramer Director
Age: 49
Bio & Compensation  - Reuters
Mark D. Chen Independent Director
Age: 45
Bio & Compensation  - Reuters
Qiang Fan Independent Director
Age: 57
Bio & Compensation  - Reuters
Chengtun Qu Independent Director
Age: 47
Bio & Compensation  - Reuters
Weirong Shen Independent Director
Age: 47
Bio & Compensation  - Reuters